Navigation Links
A reductionist approach to HIV research
Date:11/30/2009

A major obstacle to HIV research is the virus's exquisite specialisation for its human host meaning that scientists' traditional tools, like the humble lab mouse, can deliver only limited information. Now, a team of researchers writing in BioMed Central's open access Journal of Biology have made an ingenious assault on this problem by creating a mouse that has key features of HIV infection without being infected with HIV.

George Kassiotis, from the Division of Immunoregulation at MRC National Institute for Medical Research, worked with a team of researchers to create mice whose CD4+ T cells, the cells eliminated by HIV infection, commit a kind of suicide upon activation. He said, "Although these mice do not fully reproduce every aspect of human HIV-associated immune dysfunction, they do approximate two key immune alterations - CD4+ T cell immune deficiency and generalized immune activation. Further definition of the precise balance between CD4+ T cell killing and immune activation and deficiency will be vital to our understanding of the pathogenesis of immune deficiency virus infection."

The CD4+ T cells in the researchers' mice were engineered to express a toxin, diphtheria toxin A fragment, upon activation. This genetic self-destruct system causes the death of the cell within 48 hours. The resultant loss of activated immune cells caused the mice to exhibit symptoms with some similarities to those of immunodeficiency virus infection. There are clear differences between the mouse and a human infected with HIV, however, such as the fact that the ongoing depletion of nearly all activated CD4+ T cells in the mice does not result in the progressive erosion of nave and memory CD4+ T cells seen during HIV infection. None-the-less, insights gained from this reductionist model can only help our understanding of human disease. In a commentary on the work in the same issue of Journal of Biology, experts on T cells and HIV at the US National Institutes of Health comment that the mouse will be as useful for its differences from human infection as it will for its similarities.


'/>"/>

Contact: Graeme Baldwin
graeme.baldwin@biomedcentral.com
44-020-319-22165
BioMed Central
Source:Eurekalert

Related biology news :

1. ORNL, Los Alamos pioneer new approach to assist scientists, farmers
2. Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer
3. UTs Valentin Dragoi gets $1.2 million grant for groundbreaking approach to brain research
4. Systems biology recommended as a clinical approach to cancer
5. New tracking approach will help protect polar bears
6. Manatees can probably hear which directions boats approach from
7. Equity concerns raised by congestion pricing can be addressed to make approach viable
8. Combined stem cell-gene therapy approach cures human genetic disease in vitro
9. Rapid approach to identify influenza A virus mutations and drug resistance developed
10. Novel vaccine approach offers hope in fight against HIV
11. Stowers researchers develop whole genome sequencing approach for mutation discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology: